Vaccine

NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave – NV-387 is Effective Against H3N2

SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader…

3 weeks ago

Evaxion expands AI-Immunology™ platform into autoimmune diseases

Evaxion adds autoimmune disease as a third disease area as it expands its therapeutic focusIn future, Evaxion’s proprietary AI-Immunology™ platform…

3 weeks ago

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG

January 13, 2026, 7:00 AM CET  Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company…

3 weeks ago

Using Recombinant Insulin and Trypsin for Safer Vaccine Production, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn how recombinant insulin improves viral production across diverse vaccine platforms. Attendees will gain insight into…

4 weeks ago

Commonwealth Fusion Systems Names Stephane Bancel to Board of Directors

DEVENS, Mass., Jan. 12, 2026 /PRNewswire/ -- Commonwealth Fusion Systems (CFS), the largest and leading private fusion company, today announced…

4 weeks ago

Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings CallImproves 2025 expected GAAP…

4 weeks ago

Cellev8 Nutrition Welcomes Dr. Guangshuo “Alan” Zhu, MD to Its Board of Directors

WELLINGTON, FLORIDA / ACCESS Newswire / January 8, 2026 / Cellev8 Nutrition Inc., (OTCID:CELV) a leader in clinically validated antioxidant…

4 weeks ago

Ascend Advanced Therapies – ABL Inc. Further Strengthens Executive Team as It Drives Forward an Ambitious Growth Strategy

Seiga Ohmine to join as Chief Commercial Officer, Sharad Dubey as Chief Financial Officer and Patrick Lansky as Senior Vice…

4 weeks ago

BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer

Vancouver, British Columbia--(Newsfile Corp. - January 8, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or…

4 weeks ago

Services PMI® at 54.4%; December 2025 ISM® Services PMI® Report

Business Activity Index at 56%; New Orders Index at 57.9%; Employment Index at 52%; Supplier Deliveries Index at 51.8%TEMPE, Ariz., Jan.…

1 month ago